AA
AlphaCentric Advisors’s Celldex Therapeutics CLDX Stock Holding History
Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
---|---|---|---|---|---|---|---|---|
2024
Q4 | – | Sell |
-30,000
| Closed | -$1.02M | – | 224 |
|
2024
Q3 | $1.02M | Sell |
30,000
-17,500
| -37% | -$595K | 0.76% | 44 |
|
2024
Q2 | $1.76M | Buy |
47,500
+9,000
| +23% | +$333K | 1.29% | 19 |
|
2024
Q1 | $1.62M | Buy |
+38,500
| New | +$1.62M | 0.97% | 32 |
|
2023
Q4 | – | Sell |
-15,000
| Closed | -$413K | – | 237 |
|
2023
Q3 | $413K | Hold |
15,000
| – | – | 0.23% | 97 |
|
2023
Q2 | $509K | Hold |
15,000
| – | – | 0.28% | 95 |
|
2023
Q1 | $540K | Hold |
15,000
| – | – | 0.37% | 84 |
|
2022
Q4 | $669K | Sell |
15,000
-2,000
| -12% | -$89.1K | 0.66% | 56 |
|
2022
Q3 | $478K | Buy |
+17,000
| New | +$478K | 0.49% | 57 |
|
2021
Q4 | $657K | Hold |
17,000
| – | – | 0.19% | 54 |
|
2021
Q3 | $918K | Sell |
17,000
-8,000
| -32% | -$432K | 0.23% | 37 |
|
2021
Q2 | $836K | Hold |
25,000
| – | – | 0.23% | 34 |
|
2021
Q1 | $515K | Buy |
25,000
+21,500
| +614% | +$443K | 0.17% | 43 |
|
2020
Q4 | $61K | Hold |
3,500
| – | – | 0.03% | 170 |
|
2020
Q3 | $52K | Buy |
+3,500
| New | +$52K | 0.03% | 104 |
|